论文部分内容阅读
新近,一种新型肿瘤相关抗原—糖类抗原(CA19—9)已被发现。在罹患胃肠道癌瘤尤其是胰腺癌患者血情中其浓度常会升高。用人结肠癌细胞株免疫小鼠脾淋巴细胞而形成的杂交瘤可产生单克隆抗体,此抗体可检测出CA19—9。为评阶CA19—9在诊断胰腺癌上的临床价值及与CT扫描结果之间的关系,作者对一组胰腺癌患者和慢性胰腺炎患者进行了研究。本组包括:胰腺癌55例,慢性胰腺炎22例。所有胰腺癌患者切片经组织学证实均为导管腺癌。慢性胰腺炎按日本胃肠学会的诊断标准进行。胰腺癌患者在术前二周内取血清标本,然后做CT。
Recently, a novel tumor-associated antigen-carbohydrate antigen (CA19-9) has been discovered. In patients suffering from gastrointestinal cancer, especially pancreatic cancer, their concentration often increases. Hybridomas formed by immunizing mouse splenic lymphocytes with human colon cancer cell lines produce monoclonal antibodies that detect CA19-9. To assess the clinical value of CA19-9 in the diagnosis of pancreatic cancer and its relationship with CT scan results, the authors studied a group of patients with pancreatic cancer and chronic pancreatitis. This group includes: 55 cases of pancreatic cancer, 22 cases of chronic pancreatitis. All histological sections of pancreatic cancer were histologically confirmed as ductal adenocarcinoma. Chronic pancreatitis was performed according to the diagnostic criteria of the Japanese Gastroenterology Society. Patients with pancreatic cancer take serum samples within two weeks before surgery, and then do CT.